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Abstract
Background: Recurrent cardiovascular events following acute myocardial infarction (AMI) are
common. The purpose of this study was to evaluate the impact of platelet aggregation, PFA-100
closure times and peak C-reactive protein (CRP), respectively, on the occurrence of death,
myocardial infarction and ischemic cerebral events after an AMI. Furthermore, to examine the
relationship between the platelet function tests and peak CRP.
Methods: Three hundred and thirty-four patients with AMI were included in the study. Platelet
aggregation was analyzed by an aggregometer using laser light (PA-200). The state of high residual
platelet reactivity was defined as normal closure times (PFA-100) during treatment with aspirin.
Results: The fourth quartile of peak CRP was associated with poorer outcome as compared to
the first quartile in a multivariate Cox-regression analysis, with a hazard ratio of 2.0 (95% CI 1.1–
3.7) for the occurrence of death, myocardial infarction and ischemic cerebral events. The fourth
quartile of peak CRP (>64.6 mg/l) was associated with platelet aggregation (p < 0.001, adjusted R2
= 0.13) and high residual platelet reactivity, in a multivariate model, with an odds ratio of 2.9 (CI
95% 1.3–6.8), as compared to the first quartile. Neither the highest quartile of platelet aggregation
nor the state of high residual platelet reactivity predicted new cardiovascular events.
Conclusion: In patients with myocardial infarction, measured peak CRP is associated with new
cardiovascular events. Despite an association with peak CRP neither more pronounced platelet
aggregation nor PFA-100 closure times independently predict new cardiovascular events.
Introduction
Recurrent cardiovascular events following acute myocar-
dial infarction are common despite the availability of
modern anti-thrombotic and anti-platelet treatment [1-
5]. Although outcomes such as heart failure and recurrent
AMI seem to be declining over time, as treatments for
myocardial infarction improve [6-9], the issue of insuffi-
ciently inhibited platelets persists. In addition, the fact
that stroke occurrence is high early after an AMI and
declines rapidly with time suggests that the systemic
inflammatory reaction plays a role [2,4].
The tissue damage in myocardial necrosis leads to an
inflammatory reaction which is reflected for example, in
increased levels of C-reactive protein (CRP), cytokines
and fibrinogen [10,11]. The peak value of CRP during the
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hospital stay is related to the extent of the inflammatory
reaction [12], which may be associated with platelet acti-
vation. In patients with AMI, CRP is positively correlated
with expression of COX-2 in monocytes [13], which could
hypothetically promote platelet activation via Thrombox-
ane A2. Elevated CRP on admission is associated with
poorer outcome in the acute coronary syndrome and
among healthy individuals [14-17], but the relation of
peak CRP concentration, during the course of AMI, to
platelet reactivity and the risk of subsequent cardiovascu-
lar events has never been explored.
The primary purpose of this study was to evaluate the
impact of measured peak platelet aggregation, high resid-
ual platelet reactivity, defined from PFA-100 closure
times, and measured peak CRP, respectively, on the occur-
rence of cardiovascular events after an acute myocardial
infarction. Furthermore, the relationship between the
platelet function test values and measured peak CRP was
examined as a secondary purpose.
Materials and methods
Study population
Three hundred and thirty-four patients with AMI, admit-
ted to the cardiac intensive care unit at Östersund Hospi-
tal during the period January 1, 2002 to October 30, 2003,
were included in the study. Östersund Hospital is the pri-
mary hospital for the County of Jämtland with a catch-
ment area of approximately 128,000 inhabitants. All
patients with a diagnosis of AMI during the inclusion
period were considered for inclusion. An in-hospital stay
of at least three days, aspirin treatment on discharge and
complete PFA-100 and peak CRP data were required for
inclusion. Another 163 patients with AMI were admitted
to the hospital during the inclusion period but were not
included because of death (n = 19), discharge before the
required three in-hospital days (n = 71), not being on
aspirin treatment on discharge (29) or incomplete labora-
tory data (n = 64). There could be more than one reason
for a particular patient to be excluded. An acute myocar-
dial infarction was diagnosed according to the guidelines
of the European Society of Cardiology [18]. Patients
receiving any treatment for diabetes were classified as dia-
betics. No glucose tolerance tests were performed. Patients
were classified as hypertensive if they had a diagnosis of
hypertension and as smokers if they were current smokers.
Any histories of atrial fibrillation or atrial fibrillation dur-
ing current hospitalization were classified as atrial fibrilla-
tion. Any past history of ischemic cerebral event (not
necessary verified by x-ray) was classified as previous
stroke. An ischemic cerebral event was defined as the
occurrence of an ischemic stroke or a transitory ischemic
attack (TIA). Heart failure during the hospital stay was
defined as the need for intravenous furosemide or a bed-
side diagnosis of heart failure (Killip class > 1). Conven-
tional anti-platelet and anti-thrombotic treatments were
used as clinically indicated. The routinely used aspirin
dose was 75 mg per day. This study complies with the
Declaration of Helsinki and was approved by the local
ethics committee. Informed consent was obtained from
all subjects.
Primary endpoint and secondary aim
The primary endpoint of the study was the composite of
ischemic cerebral event, new myocardial infarction and
death from all causes. The median follow-up duration was
44 (interquartile range 35–55) months. Survival confir-
mation and date of deaths were obtained from the Swed-
ish National Population Registry. All survivors were
contacted for a telephone interview concerning possible
cardiovascular events. Ischemic cerebral events and myo-
cardial infarctions were verified from hospital records. As
a secondary aim we analyzed the level of measured peak
CRP concentration in relation to measured peak platelet
aggregation and high residual platelet reactivity.
Blood tests
Blood samples were obtained via venipuncture and col-
lected in tubes containing sodium citrate (0.129 M) on
admission and on days two, three and five in hospital for
the PA-200 analysis and on the third day for the PFA-100
analysis. A blood sample collected in serum tubes for CRP
analysis was obtained on days one, two, three and five
after admission. The measured peak values of PA-200 and
CRP were used in this study. CRP was measured with C-
reactive protein (latex) high sensitive immunoturbidimet-
ric assay on Modular Analytics System (Roche). The coef-
ficient of variation for the CRP analysis was 4.0% and
1.3% at the CRP-concentration level 0.94 mg/L and 17.1
mg/l respectively. The peak value of consecutive troponin
T analyses was recorded. A blood sample for troponin T
analysis was taken routinely every 8 hour. Troponin T was
measured by an electrochemiluminiscence immunoassay
(e170 Modular). GFR calculations were based on meas-
urements of cystatin C levels for each patient. Plasma
cystatin C measurements were performed by means of a
particle enhanced immunoturbidimetric method (Modu-
lar P). LDL was calculated from the serum concentrations
of cholesterol and fasting triglycerides using the Friede-
walds formula. Von Willebrand factor was measured with
an ELISA using reagents from DAKO (Copenhagen, Den-
mark). The test results (PA-200, PFA-100) were not acces-
sible by the attending physicians.
PFA-100 system testing
The PFA-100 (Platelet Function Analyzer, Dade Behring,
Leiderbach, Germany) measures platelet function as pri-
mary hemostasis capacity in citrated whole blood [19].
The cartridge with collagen and epinephrine (CEPI) was
used in the present study. The function of PFA-100 has
been well documented and is not further presented here
[20]. We defined the state of high residual platelet reactiv-Thrombosis Journal 2009, 7:12 http://www.thrombosisjournal.com/content/7/1/12
Page 3 of 10
(page number not for citation purposes)
ity as a normal closure time (CT) value even when the sub-
ject was taking aspirin [21].
Control group and reference values
For interpretation of the PFA-100 results, in house refer-
ence ranges were established from analyses in a control
group of 278 volunteers without known cardiovascular
disease (mean age 58.5 years, range 30 to 93). These indi-
viduals had no previous history or laboratory results
indicative of platelet dysfunction, meaning no anaemia,
no bleeding diathesis and normal platelet count. The use
of non-steroidal anti-inflammatory drugs was not
allowed. Since it is not unusual to find persons with mild
von Willebrand disease in a selected volunteer popula-
tion, and because individuals might be unaware that they
have actually taken aspirin-like substances, we discarded
all CT-values above the 95th percentile before defining the
normal range. The reference range (90–197 sec) was then
determined based on a 90% central interval of the results.
The coefficient of variation was calculated at 15.3% for the
collagen and epinephrine cartridge (CEPI).
PA-200 system testing
The PA-200 aggregometer (Kowa Inc, Tokyo, Japan) has
been described in detail by Ozaki and co-workers [22]. It
is a particle counting technique based on laser light scat-
tering (LS). The validity of this method has been con-
firmed in several studies [23-27]. A 20-mW diode laser
generates a laser beam measuring 40 μm (wave length 675
nm) in diameter, which is passed through 300 μl of plate-
let-rich plasma (PRP) stirred in a cylindrical glass cuvette
with a 5 mm internal diameter. Light scatter generated by
single platelets and platelet aggregates is measured within
a region of approximately 30 × 65 × 145 μm by a photo-
cell array. The signal frequency is recorded at 10-second
intervals. The light scattering intensity increases in pro-
portion to the particle size in a suspension and thus pro-
vides an estimate of platelet aggregate size in PRP. Data
are expressed as the change over time (s) in the number of
aggregates (counts/10 sec) of individual sizes (determined
by light intensity, expressed in volts). The LS signals are
digitized with an A/D converter and processed by a com-
puter. Data are recorded as a two-dimensional graph
showing the change over time (s) of the cumulative
number of aggregates (counts/10 s during 10 min). Parti-
cles with an intensity of 25 to 400 mV represent small
aggregates (9–25 μm), which are used to study platelet
activation. To obtain platelet-rich plasma, the blood sam-
ples are centrifuged at 150 g for 10 min at room tempera-
ture. The remaining blood samples are then centrifuged at
300 g for 10 min to obtain platelet-poor plasma, which is
used as a reference. As an agonist, we used 30 μL of a solu-
tion containing 0.1 mg epinephrine/L [24].
Calculation and statistics
Data were analyzed using SPSS 13.0 software. Group data
are expressed as rates for variables on a nominal scale. Dif-
ferences between two groups were assessed with the
Mann-Whitney U test. Differences between multiple
groups were assessed with the Kruskal-Wallis test. Differ-
ences between proportions were analyzed with the chi-
square test. Troponin T and CRP values were divided into
quartiles in the analyses. Repeated measurements of plate-
let activation during hospitalization were analyzed with
the non-parametric Friedman test. Independent predic-
tors of platelet aggregation measured by the PA-200 were
identified using a multiple linear regression model. Age,
CRP, troponin T, the use of low molecular weight heparin
(LMWH), and the use of clopidogrel were considered to
be of potential importance and included in the models.
An approximate normal distribution with improved
skewness and kurtosis was achieved using the square root
transformation of the PA-200 results. Independent predic-
tors of high residual platelet reactivity were identified
using a multivariate logistic regression model. The varia-
bles of age, CRP, troponin T, platelet count, von Wille-
brand factor, treatment with thrombolysis, the use of
LMWH and the use of clopidogrel were included in the
model. A power analysis indicated that in a model with a
binary independent variable an OR = 2 could be identified
with 80% power with a sample size of n = 250, p = 0.05.
One hundred and sixty-seven were classified as high resid-
ual platelet reactivity, providing sufficient precision for
the number of covariables in the model (at least 10 events
per independent variable). The relationship between peak
CRP and closure times was investigated using Spearman's
rank order correlation. We used Cox-regression analysis to
calculate the unadjusted and adjusted relative hazard
ratios and 95 percent confidence intervals for stroke, myo-
cardial infarction and death of any cause in relation to
peak CRP, platelet aggregation and the state of high resid-
ual platelet reactivity. The co-variables age, sex, smoking
status, diabetes, atrial fibrillation, clinical heart failure
(Killip class > 1), baseline glomerular filtration rate
(GFR), troponin T, platelet aggregation, high residual
platelet reactivity and intervention with CABG (CoronAry
By-pass Grafting) or PCI (Percutanous Coronary Interven-
tion) were included in the adjusted model. One hundred
and forty-one events occurred, providing sufficient preci-
sion for the number of covariables in the model (at least
10 events per independent variable). Neither use of clopi-
dogrel and low molecular weight heparin during hospital-
ization nor medications at discharge had any discernible
effects in the multivariate models. The assumptions for
Cox-regression analysis were evaluated by Kaplan-Meier
curves for all the variables included. The null hypothesis
was rejected for values of p < 0.05.Thrombosis Journal 2009, 7:12 http://www.thrombosisjournal.com/content/7/1/12
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Results
The mean age of the study population was relatively high
(72 years). Almost one third of the subjects had a history
of previous myocardial infarction. Sixteen percent had a
history of ischemic stroke. Twelve percent had a diagnosis
of heart failure and 20 percent had diabetes mellitus prior
to admission. Twenty-one percent were current smokers.
The median time from the onset of the episode of chest
pain to blood sampling was seven hours.
There were important differences in the clinical character-
istics between the different quartiles of peak CRP (Table
1). Patients with higher peak CRP levels were older, had
more impaired kidney function and more often had a his-
tory of heart failure. They were also less likely to receive an
intervention (PCI or CABG) after the AMI. Medical treat-
ment with clopidogrel, ACE-inhibitors and statins also
differed between quartiles, which reflect differences in age
of the patients and type of myocardial infarction. Among
those with higher peak CRP levels there was a higher rate
of thrombolysis. Clopidogrel was not part of the thera-
peutic regime in ST-elevation myocardial infarction. Clin-
ical heart failure and treatment with ACE-inhibitors were
more common among those with highest peak CRP con-
centration, probably reflecting more extensive myocardial
infarction. There were no differences between the groups
in the time between symptom onset and first blood sam-
pling.
The aggregation of platelets increased during the hospital
stay (p < 0.001) and was more pronounced with peak CRP
levels in the fourth quartile (p < 0.0005) (Table 2). Clo-
sure time was also shorter, with higher levels of CRP (p <
0.05). The fourth quartile of peak CRP (>64.6 mg/l) was
independently associated with increased platelet aggrega-
tion (p < 0.001, adjusted R2 = 0.13), after adjustment for
age, troponin T, platelet count, treatment with thrombol-
ysis, the use of clopidogrel and LMWH. Furthermore, the
fourth quartile of peak CRP was associated with an odds
ratio of 2.2 (CI 95% 1.2–4.0) for high residual platelet
reactivity (p = 0.003) in a univariate model and 2.9 (CI
95% 1.3–6.8) in a multivariate model, adjusted for age,
platelet count, von Willebrand factor, treatment with
thrombolysis, the use of clopidogrel and the use of
LMWH. There was a small negative correlation between
peak CRP and closure time, rho = -0.17, p = 0.002.
During a median follow-up period of 44 months (inter-
quartile range 35–55 months), 141 primary endpoint
events occurred (ischemic cerebral event, myocardial inf-
arction, or death of any cause). Median follow-up time
according to quartiles of CRP was fifty-two, fifty, forty-
four and thirty-nine months in the first, second, third and
fourth quartile, respectively. No patients were lost to fol-
low up. During the entire follow-up period a total of 28
cases of ischemic cerebral events, 65 myocardial infarc-
tions and 88 deaths occurred. The rates for the combined
endpoint of stroke, AMI and death in the different quar-
tiles of peak CRP were twenty-four (28.2%), thirty-one
(37.8%), thirty-four (40.5%) and fifty-two (62.7%) in the
first, second, third and fourth quartile, respectively (p <
0.0005).
The hazard ratios (HR) for the prognostic variables are
given in Table 3. The fourth quartile of peak CRP was asso-
ciated with poorer outcome in a univariate model with a
hazard ratio of 3.0 (95% CI 1.9–5.0) for the occurrence of
ischemic cerebral event, myocardial infarction and death
(Figure 1), as compared to the first quartile. Peak CRP pre-
dicted a worse outcome also after multivariate adjustment
for age, sex, diabetes, smoking status, heart failure, atrial
fibrillation, baseline glomerular filtration rate, troponin
T, platelet aggregation, high residual platelet reactivity,
intervention with CABG or PCI with a hazard ratio of 2.0
(95% CI 1.1–3.7) (Figure 2). Age, atrial fibrillation and
clinical heart failure also predicted a worse prognosis
(Table 3). Clinical heart failure had the second strongest
association with poorer outcome with a hazard ratio of
1.8 (95% CI 1.2–2.6.
The fourth quartile peak small platelet aggregates was
associated with poorer outcome in a univariate Cox-
regression analysis, HR 2.0 (CI 95% 1.2–3.3) (Figure 3),
but when adjustment was made for the same co-variables
as above the association was no longer there; HR 1.1 (CI
95% 0.6–2.0) (Figure 4). The state of high residual plate-
let reactivity did not predict poorer outcome in univariate
or multivariate analysis.
Discussion
This study shows that peak CRP is an independent predic-
tor of prognosis in a population of patients with AMI. In
a univariate analysis platelet aggregation was associated
with worse prognosis but not in an adjusted analysis
model. PFA-100 closure times give no prognostic infor-
mation. Obviously, the potential prognostic value of
platelet function tests has to be verified in prospective
studies with careful adjustment for relevant clinical varia-
bles.
Peak CRP had a weak association with more pronounced
peak platelet aggregation and lower PFA-100 closure
times. The question whether CRP is a marker or involved
in the mechanisms of atherothrombosis is still under
debate, and more research is needed [28]. A better under-
standing of the mechanisms involved would open for fur-
ther therapeutic improvements and more individualized
treatment regimens.
Our results add to previous knowledge about CRP as a
predictor of prognosis after an AMI. Suleiman et al.
showed that CRP was an independent predictor of heartThrombosis Journal 2009, 7:12 http://www.thrombosisjournal.com/content/7/1/12
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Table 1: Clinical characteristics and medical treatment according to quartiles of peak C-reactive protein
Quartile of C-reactive protein, (Range mg/l)
1st (n = 85)
(0.05–5.3)
2nd (n = 82)
(5.4–19.6)
3rd (n = 84)
(19.7–64.5)
4th (n = 83)
(64.6–304)
p
Female, % 35 42 27 29 0.2
Age, mean
(range)
70
(41–91)
70
(27–90)
73
(43–97)
75
(53–92)
0.02
Waist circumference, cm (SD) 95
(12)
96
(13)
96
(12)
95
(11)
1.0
Current smokers, % 19 18 25 22 0.7
Hypertension, % 29 44 35 45 0.1
Diabetes, % 16 24 26 12 0.07
Previous AMI, % 25 30 28 25 0.8
Previous stroke, % 11 15 18 13 0.6
Previous heart failure, % 11 15 8 18 0.2
Atrial fibrillation 16 16 23 23 0.5
GFR, mean (SD) 85
(33)
84
(36)
81
(35)
66
(35)
0.004
TnT peak, median μg/L 0.49
(0.21–1.26)
1.1
(0.33–2.64)
1.9
(0.92–5.18)
4.0
(2.02–7.36)
<0.0005
LDL, mean (SD) 3.5
(1.2)
3.3
(0.9)
3.2
(0.9)
3.2
(1.3)
0.3
Clinical heart failure, during hospitalization, % 18 16 30 62 <0.0005
PCI, % 31 32 21 12 0.009
CABG, % 19 11 12 11 0.4
LMWH or warfarin in hospital, % 94 88 89 80 0.04
Aspirin, at admission, % 41 55 45 43 0.3
Clopidogrel, at discharge, % 62 61 40 16 <0.005
Statins, at discharge, % 65 68 53 42 0.004
ACE inhibitors or ARBs, at discharge, % 36 49 49 61 0.02
Betablockers, at discharge, % 89 87 87 87 0.9
Thrombolysis 11 24 26 36 0.002Thrombosis Journal 2009, 7:12 http://www.thrombosisjournal.com/content/7/1/12
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failure and mortality in 1044 survivors of acute myocar-
dial infarction [29]. They measured CRP once and within
12 to 24 h of symptom onset, while in the present study
peak CRP levels during the hospital stay were analyzed.
We used peak CRP since it might better reflect the magni-
tude of the inflammatory response to myocardial necro-
sis, which we hypothesized would have an impact on
platelet reactivity. Peak CRP was only significantly associ-
ated with death among the single endpoints which could
be a power problem.
In contrast, the study by Bennermo et al. concluded that
CRP after an ST-elevation myocardial infarction treated
with thrombolysis does not carry any predictive value in a
multivariate analysis. They did not, however, present any
power calculation and their negative results might have
been due to a small study population since only 45 pri-
mary events occurred [30]. Most of the previous studies in
this area are sub-studies of randomized controlled trials
and therefore contain a highly selected patient sample.
Our study is an observational cohort study, not part of a
clinical trial, which is reflected in the presence of more
women and older patients.
We failed to show any substantial association between
outcome and platelet aggregation or the state of high
Table 2: Comparison of platelet aggregation, closure times (CT) and troponin T (TnT) levels according to quartiles of peak C-reactive 
protein (CRP)
Q u a r t i l e  1Q u a r t i l e  2Q uartile 3 Quartile 4 p
CRP, mg/l 0.05–5.3 5.4–19.6 19.7–64.5 64.6–304
Peak SPA, count, ×103 71
(22–91)
82
(30–120)
104
(45–150)
117
(70–160)
P < 0.0005
CT, sec 259
(150–300)
231
(143–300)
184
(137–300)
162
(124–300)
P < 0.05
TnT, μg/L 0.49
(0.21–1.26)
1.09
(0.33–2.64)
1.93
(0.92–5.18)
3.99
(2.02–7.36)
P < 0.0005
SPA = Small platelet aggregates. Peak SPA = The highest measured count of small platelet aggregates during hospitalization. Values are expressed as 
medians with the interquartile range in parentheses. Calculations using Kruskall-Wallis test.
Cumulative event-free survival (AMI, stroke and all death) in  relation to peak CRP quartiles Figure 1
Cumulative event-free survival (AMI, stroke and all 
death) in relation to peak CRP quartiles. Univariate 
Cox-regression analysis.
Cumulative event-free survival (AMI, stroke and all death) in  relation to peak CRP quartiles Figure 2
Cumulative event-free survival (AMI, stroke and all 
death) in relation to peak CRP quartiles. Multivariate 
Cox-regression analysis.Thrombosis Journal 2009, 7:12 http://www.thrombosisjournal.com/content/7/1/12
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Table 3: Hazard ratios (Cox regression analysis) for the combined endpoint (acute myocardial infarction, stroke, death of all causes) 
for the entire follow-up period
Variable Univariate Multivariate
Hazard ratio (95% Confidence interval)
C-reactive protein
Quartile 4
(Quartile 1 is reference)
3.0 (1.9–5.0) 2.0 (1.1–3.7)
Age (continues variable) 1.06 (1.0–1.1) 1.05 (1.0–1.1)
Sex
Male 1.0 1.0
Female 1.3 (0.9–1.8) 0.9 (0.6–1.3)
Current smoker
No 1.0 1.0
Yes 0.9 (0.6–1.4) 1.6 (1.0–2.6)
Diabetes
No 1.0 1.0
Yes 1.6 (1.1–2.4) 1.5 (1.0–2.4)
Clinical heart failure
During hospitalization
No 1.0 1.0
Yes 3.1 (2.2–4.4) 1.8 (1.2–2.6)
Atrial fibrillation
No 1.0 1.0
Yes 2.3(1.6–3.3) 1.6 (1.1–2.4)
Glomerular filtration rate
>60 ml/min 1.0 1.0
<60 ml/min 2.5 (1.8–3.5) 1.2 (0.8–1.7)
Troponin T, quartile 4
(Quartile 1 is reference)
1.7 (1.1–2.7) 1.0 (0.6–1.8)
Platelet Aggregation
Quartile 4
(Quartile 1 is reference)
2.0 (1.2–3.3) 1.1 (0.6–2.0)Thrombosis Journal 2009, 7:12 http://www.thrombosisjournal.com/content/7/1/12
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residual platelet reactivity. These findings do not support
the idea that more pronounced platelet aggregation dur-
ing hospitalization plays a long term key role in subse-
quent cardiovascular events. The fact that platelet
aggregation for the whole study population peaked in
average on the third day and was lower on day five might
theoretically indicate that pronounced platelet aggrega-
tion have the strongest impact on adverse events in the
early phase of a myocardial infarction and less importance
later on. This theory is supported by the COMMIT trial,
which showed that adding clopidogrel to aspirin only
during a mean time of 15 days in patients with myocardial
infarction reduced mortality [31].
Somewhat surprisingly, the state of high residual platelet
reactivity was not associated with poorer prognosis,
despite its relation to the systemic inflammatory response.
This finding is in contrast to a meta-analysis of "aspirin
resistance" by Krasopoulos et al., who concluded that
"aspirin resistant" patients are at greater risk of adverse
cardiovascular events [32]. Their metaanalysis however,
was a composite of various platelet function tests and clin-
High residual platelet reactivity
No 1.0 1.0
Yes 0.8 (0.5–1.1) 0.7 (0.5–1.0)
CABG
No 1.0 1.0
Yes 0.5 (0.3–0.9) 0.5 (0.3–1.0)
PCI
No 1.0 1.0
Yes 0.4 (0.3–0.7) 1.0 (0.6–1.8)
Table 3: Hazard ratios (Cox regression analysis) for the combined endpoint (acute myocardial infarction, stroke, death of all causes) 
for the entire follow-up period (Continued)
Cumulative event-free survival (AMI, stroke and all death) in  relation to peak small platelet aggregation quartiles Figure 3
Cumulative event-free survival (AMI, stroke and all 
death) in relation to peak small platelet aggregation 
quartiles. Univariate Cox-regression analysis.
Cumulative event-free survival (AMI, stroke and all death) in  relation to peak small platelet aggregation quartiles Figure 4
Cumulative event-free survival (AMI, stroke and all 
death) in relation to peak small platelet aggregation 
quartiles. Multivariate Cox-regression analysis.Thrombosis Journal 2009, 7:12 http://www.thrombosisjournal.com/content/7/1/12
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ical index episodes. Furthermore, only two studies used
the PFA-100 in acute coronary syndrome and neither of
these had a prospective design [33,34]. Two studies used
different aggregometry techniques in acute coronary syn-
drome, and one showed no relationship between platelet
aggregation and cardiovascular events. The second study,
which used cationic propyl gallate platelet aggregometry,
showed an almost two-fold increased frequency of new
cardiovascular events during a 4-year follow up. They did
not, however, adjust for important clinical entities in their
statistics, such as the occurrence of diabetes, smoking sta-
tus, kidney function, heart failure, and so on. In addition,
several other studies show a prognostic value of PFA-100,
but most of the prospective studies included patients with
chronic conditions, and not ACS patients with signs of
systemic inflammatory response. Differences in patient
populations and lack of adjustment for confounding var-
iables are important reasons for the variance in the results
[35]. In our study, we recorded 141 endpoints. The
number of endpoints in previous studies was fairly low,
ranging from three to just over one hundred, indicating a
power problem.
The present study does not support an independent pre-
dictive value of PA-200 or PFA-100 results in terms of
future cardiovascular events. On the contrary, our results
reinforces the importance of clinical variables such as
heart failure, age, atrial fibrillation, diabetes and smoking
status all of which were associated with worse prognosis
in a multivariate analysis.
Limitations of the study
It is difficult to rule out a problem with insufficient power
concerning the analysis of PA-200 and PFA-100 results as
predictors of prognosis in the present study. Therefore, we
might have failed to reject the null-hypothesis (type 2-
error). The finding of positive results in previous studies
with fewer participants might on the other hand have
been due to chance (type 1-error), because it is generally
believed that there is selection bias in relation to these
types of studies, implying that papers with negative results
are not published.
The association between CRP and cardiovascular events
diminished substantially in the adjusted model. It is pos-
sible that there exist other factors of importance for prog-
nosis that has not been adjusted for. We used clinical
measures of heart failure as a prognostic variable.
Although this variable was significantly related with prog-
nosis a direct measurement of ventricular function might
have added to the model.
Since this was not a controlled study we could not control,
for example, for compliance to medication. This is an
observational cohort study with its inherent limitations of
possible confounding factors. The normal range of CT is
wide and the appropriate cut off value for insufficiently
inhibited platelets remains to be determined.
Conclusion
Peak CRP during the course of an acute myocardial infarc-
tion is associated with new cardiovascular events during
long-term follow up. Neither PFA-100 closure times nor
peak platelet aggregation independently predict progno-
sis. There is an association between elevated CRP and
more pronounced platelet aggregation as well as high
residual platelet reactivity, the latter assessed using PFA-
100. However, this study does not support the idea that
the association between inflammation and subsequent
cardiovascular events in the long term goes via more pro-
nounced platelet aggregation or by high residual platelet
reactivity. To adequately explore the relationships in the
short term, a larger study is needed. Clinical variables
retain important prognostic information.
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